Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To date, researchers have discovered that Nrf2 deletion results in high susceptibility and severity of insults in various models of respiratory diseases, including bronchopulmonary dysplasia (BPD), respiratory infections, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, idiopathic pulmonary fibrosis (IPF), and lung cancer.
|
30728889 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in KEAP1/NFE2L2 genes always cause persistent Nrf2 activation in lung cancer cells that confer therapeutic resistance and aggressive tumorigenic activity, dictating either poor prognosis or short duration of response to chemotherapy in clinical observations.
|
30556750 |
2019 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Human lung cancer biopsies expressed higher levels of Nrf2 and HO-1 compared with normal tissues.
|
31227482 |
2019 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data demonstrate that KEAP1/NRF2-mutant lung cancer is a microenvironmentally distinct, biologically heterogeneous, and clinically underestimated disease.
|
30411339 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the results indicate that NRF2 and glutathione levels figure as important cisplatin resistance biomarkers in lung cancer.
|
31776385 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although dietary antioxidant supplementation or activation of endogenous antioxidants by NRF2 reduces oxidative stress and promotes early lung tumor progression, little is known about its effect on lung cancer metastasis.
|
31257027 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop.
|
31695040 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we summarize the recent advances in NRF2-addicted lung cancer.
|
31574294 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that Nrf2 activates a metastatic program by inhibiting the heme- and Fbxo22-mediated degradation of Bach1, and that Ho1 inhibitors represent an effective therapeutic strategy to prevent lung cancer metastasis.
|
31257023 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
|
31416841 |
2019 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HHT significantly suppressed NRF2 and ARE-dependent gene expression in human lung carcinoma A549 cells.
|
31270017 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, FAM129B reduces chemosensitivity by augmenting Nrf2 antioxidative signaling and confers poor prognosis in breast and lung cancer.
|
31262713 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
An in vivo study in mice xenotransplanted with A549 cells to further explore the therapeutic potential of K-563 revealed that it also inhibited Keap1/Nrf2 pathway in lung cancer tumors.
|
30735010 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>KEAP1</i> silencing by promoter methylation is widely reported in solid tumors as part of the complex regulation of the KEAP1/NRF2 axis, but its prognostic role remains to be addressed in lung cancer.
|
31159323 |
2019 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This meta-analysis suggests that high Nrf2 expression may be a predictive factor of poor outcomes in lung cancer.
|
31298052 |
2019 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, potential avenues and implications for therapeutic targeting of KEAP1-NRF2 pathway vulnerabilities for lung cancer patients will be highlighted.
|
30009666 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer.
|
28976703 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
They found that lico A significantly promoted the tumor-suppressor miR-144-3p expression, so as to up-regulate ER stress-response protein CHOP (CCAAT/-enhancer-binding protein homologous protein) by down-regulating nuclear factor E2-related factor 2 (Nrf2), finally inducing apoptotic cell death in lung cancer.
|
30709582 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intriguingly, the signalling molecules perturbed by CCRK are divergent and cancer-specific, including the cell cycle regulators CDK2, cyclin D1, cyclin E and RB in glioblastoma, ovarian carcinoma and colorectal cancer, and KEAP1-NRF2 cytoprotective pathway in lung cancer.
|
29360538 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2.
|
30542710 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proteasome Inhibitor-Induced IκB/NF-κB Activation is Mediated by Nrf2-Dependent Light Chain 3B Induction in Lung Cancer Cells.
|
30396235 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Resistance to gefitinib and cross-resistance to irreversible EGFR-TKIs mediated by disruption of the Keap1-Nrf2 pathway in human lung cancer cells.
|
29812969 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, our results confirmed a protective role for Nrf2 in late-stage carcinogenesis and, unexpectedly, suggest that activation of Nrf2 in immune cells may be advantageous for preventing or treating lung cancer.Antioxid.Redox Signal.
|
29634345 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our results suggest that CDK20 positively modulate the KEAP1-NRF2 cytoprotective pathway to regulate tumor progression and radiochemoresistance, implying that CDK20 is a novel, promising therapeutic target for lung cancer.
|
28534518 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.
|
28504720 |
2017 |